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Introduction
============

Balancing cellular oxygen supply and demand is a key therapeutic approach to protecting organs such as the brain, kidneys and heart from ischemic injury. Permissive hypothermia and active cooling have been shown to reduce oxygen demands in patients experiencing stroke, cardiac arrest, cardiac surgery, severe trauma and other instances of ischemia and subsequent reperfusion \[[@B1]-[@B4]\]. However, hypothermic reduction of aerobic metabolism has been associated with adverse effects, including increased rates of infection and coagulopathy \[[@B5],[@B6]\]. Developing other methods to acutely reduce metabolism in patients could be clinically useful.

Hydrogen sulfide (H~2~S) is an inhibitor of cytochrome C oxidase in the mitochondrial electron transport chain \[[@B7]\] that reduces metabolism and body temperature in mice and rats \[[@B8],[@B9]\]. Inhalation of H~2~S or intravenous administration of H~2~S donor compounds (NaHS or Na~2~S) can protect rodents from hypoxia \[[@B10]\] or hemorrhagic shock \[[@B11]\], improve survival rates after cardiac arrest and cardiopulmonary resuscitation in mice \[[@B12]\], and attenuate myocardial ischemia-reperfusion injury in both rodents \[[@B13]\] and pigs \[[@B14]\].

Although inhaling H~2~S at 60 to 80 ppm reduces metabolism in mice, it has been reported that inhaled H~2~S does not depress total CO~2~production (${\overset{˙}{\text{V}}\text{CO}}_{\text{2}}$) and total O~2~consumption (${\overset{˙}{\text{V}}\text{O}}_{\text{2}}$) in sedated, spontaneously breathing sheep (60 ppm H~2~S) \[[@B15]\] or anesthetized, ventilated piglets (20 to 80 ppm H~2~S) \[[@B16]\]. On the other hand, Struve *et al*. \[[@B8]\] reported that inhalation of H~2~S at 200 to 400 ppm, but not at 30 to 80 ppm, decreased body temperature in rats. Similarly, Morrison *et al*. \[[@B11]\] showed that inhaling H~2~S at 300 ppm was required to decrease ${\overset{˙}{\text{V}}\text{CO}}_{\text{2}}$ in rats, in contrast to 80 ppm in mice. While these observations suggest that higher levels of H~2~S are likely to be required to alter metabolic rates in larger animals \[[@B11]\], the effects of higher concentrations of H~2~S on metabolism in larger mammals have not been examined.

It is well documented, however, that inhalation of high concentrations of H~2~S may injure the bronchial mucosa, cause pulmonary edema, and impair gas exchange \[[@B17],[@B18]\]. To examine the impact of delivering higher concentrations of H~2~S to the body without incurring the pulmonary toxicity of H~2~S inhalation, we administered H~2~S gas via an extracorporeal membrane lung (ECML). We hypothesized that high concentrations of H~2~S delivered via ECML in a partial venoarterial bypass system delivering blood to the aortic root might reduce the metabolic rate in sheep at rest. If ECML ventilation with H~2~S was found to reduce the metabolic rate in sheep, this method might provide a novel approach to balance the supply and demand of oxygen in a variety of situations, including in those patients who are supported by extracorporeal circulation during cardiac surgery or severe acute respiratory distress.

Materials and methods
=====================

All procedures described here were approved by the Subcommittee on Research Animal Care of the Massachusetts General Hospital, Boston, MA, USA, and adhered to the principles of the Declaration of Helsinki and the Recommendations for the Care and Use of Animals.

Animal housing and maintenance
------------------------------

Five female purebred Polypay sheep (body weight: 30.6 ± 2.5 kg, mean ± SD) were obtained from a single-source breeder (New England Ovis LLC, Rollinsford, NH, USA) and were housed under standard environmental conditions (air-conditioned room at 22°C, 50% relative humidity, 12-hour light-dark cycle) for at least 5 days prior to each study. Animals were fed standard chow (Rumilab diet 5508; PMI Feeds Inc., St. Louis, MO, USA) twice daily and were fasted for 24 hours with free access to water before each experiment.

Instrumentation
---------------

After intramuscular premedication with 5 mg/kg ketamine (ketamine hydrochloride; Hospira Inc., Lake Forest, IL, USA) and 0.1 mg/kg xylazine (Anased; Lloyd Laboratories, Shenandoah, IA, USA), a venous cannula (Surflo IV catheter 18G; Terumo, Elkton, MD, USA) was inserted into an ear vein and a bolus of 0.1 to 0.2 mg/kg diazepam (Diazepam USP; Hospira, Lake Forest, IL, USA) administered intravenously (iv). Subsequently, the animals were placed in a supine position and were intubated and mechanically ventilated with a volume-controlled mode (fraction of inspired oxygen (F~i~O~2~) 50%, tidal volume 10 ml/kg) (7200 Series Ventilator System; Puritan Bennett, Boulder, CO, USA). Anesthesia was maintained by a constant rate infusion of ketamine at 3 mg∙kg^-1^∙h^-1^and diazepam at 0.5 mg∙kg^-1^∙h^-1^. Respiratory rate was adjusted to maintain the end-tidal CO~2~between 35 and 40 mmHg. An arterial catheter (18G, FA-04018; Arrow Inc., Reading, PA, USA) was placed into the right femoral artery via percutaneous puncture to monitor mean arterial pressure (MAP) and to sample blood. Subsequently, an 8-Fr heptalumen pulmonary artery catheter (746HF8; Edwards Lifesciences, Irvine, CA, USA) was introduced through a percutaneous sheath (9 Fr, PB-09903; Arrow Inc., Reading, PA, USA) into the left external jugular vein for blood sampling and monitoring of mean pulmonary artery pressure (MPAP), central venous pressure (CVP), pulmonary capillary wedge pressure (PCWP), continuous cardiac output (CO) and blood temperature. Finally, a transurethral bladder catheter and a transesophageal gastric tube were inserted to drain urine and gastric secretions. During the first hour after induction, animals received an infusion of 500 ml of 6% hetastarch (Hextend; Hospira, Lake Forest, IL, USA) and 500 ml of lactated Ringer\'s solution (Baxter, Deerfield, IL, USA); thereafter, 16 ml∙kg^-1^∙h^-1^of lactated Ringer\'s solution and 9 ml∙kg^-1^∙h^-1^of 0.9% saline were infused to match fluid losses from diuresis and gastric secretions.

Extracorporeal circulation
--------------------------

A 20-Fr single-stage venous cannula (DLP; Medtronic, Minneapolis, MN, USA) and a 14-Fr arterial cannula (Fem-Flex II; Medtronic) were surgically inserted and advanced through the right external jugular vein and right common carotid artery, respectively, thereby enabling blood withdrawal from the superior vena cava and arterial blood return to the aortic root from the extracorporeal cardiopulmonary bypass circuit. The bypass circuit comprised a three-eighths-inch polyethylene tubing line (3506; Medtronic), an occlusive roller pump (Cardiovascular Instruments Corp., Wakefield, MA, USA) and an ECML (Trillium 541TT Affinity; Medtronic) with an integral heat exchanger, and it was primed with a total extracorporeal priming volume of 500 ml of 0.9% saline. A bolus injection of unfractionated heparin (200 IU/kg heparin sodium; APP Pharmaceuticals, LLC, Schaumburg, IL, USA) prior to cannulation, followed by a continuous infusion of 200 IU/kg unfractionated heparin per hour was used for anticoagulation. A thermostat-controlled water bath (Haake DC10-P5; Thermo Scientific, Waltham, MA, USA) supplying the heat exchanger with circulating water was maintained at 38°C. The gas compartment of the oxygenator was ventilated at a constant flow of 5 l/min with oxygen, air and H~2~S (10,000 ppm hydrogen sulfide balanced with nitrogen; Airgas Specialty Gases, Port Allen, LA, USA) blended to achieve an oxygen concentration of 21% with 0, 100, 200, or 300 ppm H~2~S.

A handheld iTX Multi-Gas detector (1 ppm detection threshold; Industrial Scientific, Oakdale, PA, USA) was used to monitor the H~2~S concentrations at the inlet and outlet of the gas compartment.

Experimental procedures
-----------------------

Once partial venoarterial bypass perfusion was started, the transmembrane blood flow was gradually increased to 1 l/min. Then the respiratory rate was reduced to maintain an end-tidal partial pressure of CO~2~of 35 to 40 mmHg, and sheep were paralyzed (0.1 mg∙kg^-1^∙h^-1^of pancuronium bromide iv; Sicor Pharmaceuticals, Irvine, CA, USA) to prevent spontaneous respiratory activity, asynchronous ventilation and excessive skeletal muscle O~2~consumption. A 1-hour equilibration period was allowed to achieve hemodynamic stability before baseline measurements were taken.

During the following 6 hours, the ECML gas compartment was alternately ventilated with either air or air plus H~2~S for 1-hour intervals, thereby administering 0 ppm H~2~S during the first hour, 100 ppm H~2~S during the second hour, followed by 0 and 200 ppm during the third and fourth hours and finally 0 and 300 ppm H~2~S during the fifth and sixth hours. This procedure was chosen to detect the hemodynamic and metabolic effects of exposure to increasing H~2~S concentrations through the membrane lung, as well as their reversibility.

Measurements and monitoring
---------------------------

A digital data acquisition system (PowerLab and Chart software version 5.0; ADInstruments, Colorado Springs, CO, USA) was used to continuously record MAP, CVP and MPAP. A Vigilance II Monitor (Edwards Lifesciences) was used to continuously measure CO and central blood temperature. End-tidal CO~2~, as well as the total amount of CO~2~exhaled from the biological lungs per unit of time (${\overset{˙}{\text{V}}}_{\text{L}}\text{CO}_{\text{2}}$), was measured by an in-stream, noninvasive, continuous monitoring device (NICO Cardiopulmonary Management System; Philips Respironics, Murrysville, PA, USA). Blood gas tensions, hemoglobin concentrations, and acid-base balances were determined in arterial and mixed venous blood samples using a standard blood gas analyzer (ABL 800 Flex; Radiometer, Copenhagen, Denmark).

Plasma concentrations of H~2~S were measured in duplicate as total sulfide concentrations using the methylene blue formation method with modifications \[[@B19]\]. Briefly, arterial and ECML-efferent blood was sampled and immediately centrifuged at 4°C to obtain plasma. An aliquot of plasma (100 μl) was added with 2% zinc acetate (200 μl) to trap the H~2~S, and 10% trichloroacetic acid (200 μl) was added to precipitate plasma proteins, immediately followed by 20 mM *N*,*N*-dimethyl-1,4-phenylenediamine sulfate in 7.2 M HCl (100 μl) and 30 mM FeCl~3~in 1.2 M HCl (100 μl). The reaction mixture was incubated for 20 minutes at room temperature and centrifuged at 14,000 rpm for 10 minutes. The absorbance of the supernatant was measured at 670 nm using a spectrophotometer. Total sulfide concentration was calculated against a standard curve made with known concentrations of Na~2~S solutions in phosphate-buffered saline. The lower detection limit of this assay was approximately 1 μM sulfide in plasma.

Calculation of carbon dioxide production
----------------------------------------

Total ${\overset{˙}{\text{V}}\text{CO}}_{\text{2}}$ was monitored continuously and was calculated as the sum of CO~2~exhaled from the lungs per unit of time (${\overset{˙}{\text{V}}}_{\text{L}}\text{CO}_{\text{2}}$) and the amount of CO~2~removed from the circulation via the membrane oxygenator (${\overset{˙}{\text{V}}}_{\text{M}}\text{CO}_{\text{2}}$), according to the following equations:

$${\overset{˙}{\text{V}}}_{\text{L}}\text{CO}_{\text{2}} = {\overset{˙}{\text{V}}}_{\text{E}} \times F_{\text{E}}\text{CO}_{\text{2}},$$

where ${\overset{˙}{\text{V}}}_{\text{E}}$ is the expiratory minute volume and *F*~E~CO~2~is the mean fraction of CO~2~in expired air. Quantification of ${\overset{˙}{\text{V}}}_{\text{E}}$ and *F*~E~CO~2~and the calculation of ${\overset{˙}{\text{V}}}_{\text{L}}\text{CO}_{\text{2}}$ were accomplished by a continuous noninvasive NICO device (see \'Measurements and monitoring\' section):

$${\overset{˙}{\text{V}}}_{\text{M}}\text{CO}_{\text{2}} = \text{Q}_{\text{gas}} \times F_{\text{M}}\text{CO}_{\text{2}},$$

where Q~gas~is the total gas flow exhausted from the membrane oxygenator and *F*~E~CO~2~is the fraction of CO~2~in the exhaust gas. Q~gas~was continuously monitored by a microturbine flow meter (S-113 Flo-Meter; McMillan Co., Georgetown, TX, USA), and *F*~E~CO~2~was measured by a sidestream infrared CO~2~analyzer (WMA-4; PP-Systems, Amesbury, MA, USA).

Calculation of oxygen consumption
---------------------------------

Total ${\overset{˙}{\text{V}}\text{O}}_{\text{2}}$ was calculated on the basis of blood samples drawn 10 minutes before the end of each period of exposure to air or H~2~S as follows:

$${\overset{˙}{\text{V}}\text{O}}_{\text{2}} = \text{(c}_{\text{a}}\text{O}_{\text{2}}\text{-c}_{\text{v}}\text{O}_{\text{2}}\text{)} \times \text{Q}_{\text{L}}\text{-(c}_{\text{e}}\text{O}_{\text{2}}\text{-c}_{\text{a}}\text{O}_{\text{2}}\text{)} \times \text{Q}_{\text{M}},$$

where c~a~O~2~is the oxygen content of arterial blood, c~v~O~2~is the oxygen content of mixed venous blood, Q~L~is transpulmonary blood flow (here meaning continuous CO measured via pulmonary artery catheter), c~e~O~2~is the oxygen content of ECML-efferent blood and Q~M~is extrapulmonary blood flow (here meaning transmembrane blood flow). Blood oxygen content (cO~2~) was calculated according to the following general equation:

$$\text{cO}_{\text{2}} = \text{[Hb]} \times F\text{O}_{\text{2}}\text{Hb} \times \text{1}\text{.34} + \text{pO}_{\text{2}} \times \text{0}\text{.003},$$

where \[Hb\] is the hemoglobin concentration, *F*O~2~Hb is the fraction of oxyhemoglobin, 1.34 is Hüfner\'s constant and pO~2~is the oxygen tension.

Statistical analysis
--------------------

Statistical analysis was performed using the SPSS 14.0 data package for Windows (SPSS, Chicago, IL, USA) and GraphPad Prism version 5.02 software (GraphPad Software, La Jolla, CA, USA). All data are reported as means ± SD unless indicated otherwise. Hemodynamic parameters, ${\overset{˙}{\text{V}}\text{CO}}_{\text{2}}$ and body temperature were measured continuously and are reported as the mean value derived from the last 10 minutes of each period of exposure to air or H~2~S. In addition, hemodynamic parameters were averaged every 5 minutes for a time course analysis, and these data are displayed in Figures [1](#F1){ref-type="fig"} and [2](#F2){ref-type="fig"}. Blood gas tension analysis, determination of blood hemoglobin concentrations and quantification of H~2~S plasma concentrations required blood sampling. Samples were obtained during the last 5 minutes of each period of exposure. Depending on the distribution of the data as determined using the Shapiro-Wilk test for normal distribution, either Student\'s *t*-test or the Wilcoxon signed-rank test was performed to compare each H~2~S ventilation period with the respective baseline period (0 ppm H~2~S). Statistical significance was assumed at *P*≤ 0.05. On the basis of data derived from pilot experiments, power and sample size calculations were performed using PS: Power and Sample Size Calculation version 2.1.31 software by Dupont and Plummer \[[@B20]\].

![**Systemic vascular hemodynamics**. Systemic vascular hemodynamics in five sheep challenged with alternate exposure to hydrogen sulfide (H~2~S) (gray bars) by ventilation of an extracorporeal membrane lung with 0 or 100 ppm H~2~S in air, 200 ppm H~2~S in air and 300 ppm H~2~S in air for 1-hour intervals each. Data are presented as means ± standard error of the mean. MAP, mean arterial pressure; CO, cardiac output; SVR, systemic vascular resistance; ppm, parts per million.](cc10016-1){#F1}

![**Pulmonary vascular hemodynamics**. Pulmonary vascular hemodynamics in five sheep challenged with alternate exposure to hydrogen sulfide (H~2~S) (gray bars) by ventilation of an extracorporeal membrane lung with 0 or 100 ppm H~2~S in air, 200 ppm H~2~S in air and 300 ppm H~2~S in air for 1-hour intervals each. Data are presented as means ± standard error of the mean. MPAP, mean pulmonary artery pressure; CO, cardiac output; PVR, pulmonary vascular resistance; ppm, parts per million.](cc10016-2){#F2}

Results
=======

Metabolic effects of H~2~S administration
-----------------------------------------

The baseline ${\overset{˙}{\text{V}}\text{CO}}_{\text{2}}$ value was stably near approximately 3.4 ml∙kg^-1^∙min^-1^when the ECML was ventilated with air. Direct diffusion of H~2~S into blood via the ECML at 100, 200 or 300 ppm did not alter ${\overset{˙}{\text{V}}\text{CO}}_{\text{2}}$ (Figure [3](#F3){ref-type="fig"}) or ${\overset{˙}{\text{V}}\text{O}}_{\text{2}}$(Figure [4](#F4){ref-type="fig"}). The temperature of the ECML heat exchanger water bath was kept at 38°C and resulted in a constant central blood temperature of 37.4 ± 0.4°C throughout the experiment (Table [1](#T1){ref-type="table"}).

![**Carbon dioxide production during administration of hydrogen sulfide (H**~**2**~**S)**. Total carbon dioxide production (${\overset{˙}{\text{V}}\text{CO}}_{\text{2}}$) in five sheep challenged with alternate exposure to H~2~S by ventilation of an extracorporeal membrane lung with 0 or 100 ppm H~2~S in air, 200 ppm H~2~S in air and 300 ppm H~2~S in air for 1-hour intervals each. Values are derived from the last 10 minutes of each period of exposure to air or H~2~S and are presented as means ± standard error of the mean. ppm, parts per million; n.s. = *P*\> 0.05.](cc10016-3){#F3}

![**Oxygen consumption during administration of hydrogen sulfide (H**~**2**~**S)**. Total carbon dioxide production (${\overset{˙}{\text{V}}\text{O}}_{\text{2}}$) in five sheep challenged with alternate exposure to H~2~S by ventilation of an extracorporeal membrane lung with 0 or 100 ppm H~2~S in air, 200 ppm H~2~S in air and 300 ppm H~2~S in air for 1-hour intervals each. Values are derived from blood samples taken during the last 10 minutes of each period of exposure to air or H~2~S and are presented as means ± standard error of the mean. ppm, parts per million; n.s. = *P*\> 0.05.](cc10016-4){#F4}

###### 

Hemodynamics and blood gas data^a^

  Parameter                                                 0 ppm           100 ppm         0 ppm           200 ppm          0 ppm           300 ppm
  --------------------------------------------------------- --------------- --------------- --------------- ---------------- --------------- ------------------
  Hemodynamics, means ± SD                                                                                                                   
   HR, beats/min                                            139 ± 24        148 ± 29        154 ± 5         172 ± 28         165 ± 28        150 ± 31
   MAP, mmHg                                                110 ± 13        117 ± 14        115 ± 11        128 ± 16         121 ± 15        66 ± 11^b^
   MPAP, mmHg                                               15 ± 3          19 ± 3\*        19 ± 3          22 ± 4           20 ± 4.0        31 ± 7^b^
   CO, l/min                                                4.6 ± 1.4       4.9 ± 2.0       5.1 ± 1.5       5.2 ± 1.7        5.8 ± 2.3       5.5 ± 1.2
   CVP, mmHg                                                9 ± 2           9 ± 1.0         10 ± 1          11 ± 2           11 ± 1          11 ± 2
   PCWP, mmHg                                               7 ± 2           7 ± 2           7 ± 8           8 ± 2            9 ± 2           10 ± 2
   SVR, dyn·s/cm^5^                                         1,843 ± 435     1,948 ± 525     1,734 ± 412     2,009 ± 703^b^   1,561 ± 553     870 ± 138^b^
   PVR, dyn·s/cm^5^                                         145 ± 32        191 ± 52^b^     203 ± 36        255 ± 70^b^      138 ± 27        279 ± 138^b^
  Hb, pH, blood gas tensions, and temperature, means ± SD                                                                                    
   Hb~a~, g/dl                                              8.6 ± 1.3       9.0 ± 1.3       9.1 ± 1.0       11.1 ± 1.4^b^    9.5 ± 0.6       9.6 ± 1.2
   pH~a~                                                    7.401 ± 0.072   7.369 ± 0.079   7.375 ± 0.051   7.346 ± 0.063    7.312 ± 0.089   7.217 ± 0.064^b^
   P~a~O~2~, mmHg                                           161 ± 28        150 ± 40        150 ± 37        107 ± 39         114 ± 36        83 ± 23^b^
   P~a~CO~2~, mmHg                                          38 ± 13         38 ± 11         35 ± 7          34 ± 5           36 ± 7.0        38 ± 4
   pH~v~                                                    7.383 ± 0.074   7.360 ± 0.080   7.360 ± 0.056   7.346 ± 0.066    7.302 ± 0.087   7.210 ± 0.068^b^
   P~v~O~2~, mmHg                                           50 ± 5          52 ± 6^b^       52 ± 4          54 ± 4           56 ± 4          52 ± 7
   P~v~CO~2~, mmHg                                          41 ± 14         41 ± 11         38 ± 8          35 ± 5           38 ± 6          40 ± 4
   Temperature,°C                                           37.5 ± 0.6      37.5 ± 0.4      37.5 ± 0.3      37.3 ± 0.4       37.3 ± 0.4      37.1 ± 0.5

^a^Hemodynamics and blood gas data in five sheep challenged with alternate exposure to H~2~S by ventilation of an extracorporeal membrane lung with 0 or 100 ppm H~2~S, 200 ppm H~2~S or 300 ppm H~2~S in air for 1-hour intervals each. ppm, parts per million; HR, heart rate; MAP, mean arterial pressure; MPAP, mean pulmonary artery pressure; CO, cardiac output; CVP, central venous pressure; PCWP, pulmonary capillary wedge pressure; SVR, systemic vascular resistance; PVR, pulmonary vascular resistance; Hb~a~, arterial hemoglobin concentration; pH~a~, arterial pH; P~a~O~2~, arterial oxygen tension; P~a~CO~2~, arterial carbon dioxide tension; pH~v~, mixed venous pH; P~v~O~2~, mixed venous oxygen tension; P~v~CO~2~, mixed venous carbon dioxide tension. All values are means ± SD and reflect the last 10 minutes of each 1-hour period. *n*= 5. Values during H~2~S exposure were compared using Student\'s *t*-test or the Wilcoxon signed-rank test with the preceding 0 ppm baseline period, that is, first vs. second hour, third vs. fourth hour and fifth vs. sixth hour; ^b^*P*≤ 0.05.

Hemodynamic effects of H~2~S administration
-------------------------------------------

After 1 hour of exposure to either 100 or 200 ppm H~2~S via ECML ventilation and partial venoarterial perfusion, MAP was not different from baseline. However, exposure to 300 ppm H~2~S for 1 hour decreased MAP from 121 ± 15 mmHg to 66 ± 11 mmHg and reduced systemic vascular resistance (SVR) from 1561 ± 553 dyn·s/cm^5^to 870 ± 138 dyn·s/cm^5^(Table [1](#T1){ref-type="table"}). We noted that MAP increased transiently during exposure to 100 and 200 ppm H~2~S (Figure [1](#F1){ref-type="fig"}) and that this increase was rapidly reversed upon application of air without added H~2~S. Subsequently, exposure to 300 ppm H~2~S induced a biphasic systemic pressor response characterized by increased MAP and SVR during the first 20 minutes of H~2~S exposure followed by a rapid decrease of MAP and pronounced irreversible hypotension (Figure [1](#F1){ref-type="fig"}).

MPAP and pulmonary vascular resistance (PVR) increased in response to H~2~S exposure, with the greatest increase (ΔMPAP, approximately 10 mmHg; ΔPVR, +51%) observed in response to 300 ppm H~2~S (Table [1](#T1){ref-type="table"}). Time course analysis (Figure [2](#F2){ref-type="fig"}) suggested that PVR increased after exposure to 100, 200 and 300 ppm H~2~S in a reversible, dose-dependent manner. Heart rate and CO did not change in response to H~2~S exposure.

Pulmonary gas exchange and acid-base status
-------------------------------------------

Arterial CO~2~tension levels were within physiological limits throughout the experiment and did not change in response to H~2~S. Mixed venous CO~2~tension (P~v~CO~2~) ranged between 35 and 41 mmHg and did not change in response to H~2~S. While arterial oxygenation (P~a~O~2~) was not significantly affected by 100 or 200 ppm H~2~S, P~a~O~2~decreased from 114 ± 36 to 83 ± 23 mmHg (*P*≤ 0.05) upon administration of 300 ppm H~2~S. Arterial oxygen tension did not recover during the subsequent interval of air exposure without H~2~S. Mixed venous O~2~tension ranged between 50 and 56 mmHg, and there was no relevant change upon H~2~S administration. While arterial pH (pH~a~) was within physiological limits throughout the experiment, significant metabolic acidosis was observed during exposure to 300 ppm H~2~S, with concomitant changes in mixed venous pH. Arterial hemoglobin concentrations were near 9 g/dl throughout the experiment. Exposure to 200 ppm H~2~S transiently increased hemoglobin concentrations by 2 ± 0 g/dl (Table [1](#T1){ref-type="table"}).

Total plasma sulfide concentrations
-----------------------------------

Plasma sulfide concentrations were determined in duplicate from arterial and ECML-efferent blood. The baseline plasma concentration of sulfide was 1.9 ± 0.3 μM, and this value was only slightly higher than the lower detection limit (approximately 1 μM) for this assay. Ventilation of ECML with air did not affect plasma sulfide concentrations in the efferent blood of the ECML. In ECML-efferent blood, plasma sulfide concentration increased to 7 ± 6, 27 ± 6 and 62 ± 12 μM/l during ECML ventilation with 100, 200 and 300 ppm H~2~S, respectively. However, no sulfide was detected in plasma samples of blood collected from the femoral artery during exposure to 100, 200 or 300 ppm H~2~S.

Discussion
==========

The results of the present study reveal that ventilating an ECML with up to 300 ppm H~2~S in venoarterial cardiac bypass circulation does not reduce whole body CO~2~production or O~2~consumption in anesthetized sheep. In addition, we have demonstrated that administration of 300 ppm H~2~S via ECML ventilation causes significant adverse effects, including pulmonary vasoconstriction, systemic vasodilation and hypoxemia. The current results do not support the hypothesis that high concentrations of H~2~S delivered via an ECML can reduce the metabolic rate in large mammals at rest.

In an attempt to bypass the direct pulmonary toxicity of inhaled H~2~S, we used an ECML to directly diffuse high concentrations of H~2~S gas into the blood. The absence of H~2~S (lower limit of detection 1 ppm) in the gas outlet of the artificial lung during ventilation with up to 300 ppm H~2~S indicates that H~2~S is highly diffusible into blood through the membrane and that a single passage is sufficient for complete uptake of the gas. Thus, assuming complete uptake of H~2~S during ventilation of the ECML at a gas flow of 5 l/min with 300 ppm H~2~S (at standard conditions for temperature and pressure), a total amount of 1.5 ml of H~2~S (that is, approximately 67 μM) are administered via the membrane every minute. This sums to about 134 μM H~2~S/kg per hour delivered to a 30-kg sheep in the current study. In contrast, the total amount of H~2~S administered in previous studies in sheep \[[@B15]\] and pigs \[[@B16]\] were approximately 13 μM/kg/h and approximately 42 μM/kg/h, respectively, assuming complete uptake of H~2~S from the alveolar space and an alveolar ventilation of 6 l/min in a 74-kg sheep, and 1.2 l/min in a 6-kg pig. Therefore, the systemic dose of H~2~S supplied in the present study was about three times greater than that applied in pigs and 10 times greater than the dose applied in sheep. If any of the alveolar H~2~S were exhaled, the ratio of the uptake via the membrane artificial lung in the present study and the uptake via the natural lungs in previous reports would be even greater. Nonetheless, our measurements suggest that administration of H~2~S up to 134 μM/kg/h does not reduce ${\overset{˙}{\text{V}}\text{CO}}_{\text{2}}$ or ${\overset{˙}{\text{V}}\text{O}}_{\text{2}}$ in sheep.

While H~2~S did not reduce ${\overset{˙}{\text{V}}\text{CO}}_{\text{2}}$ or ${\overset{˙}{\text{V}}\text{O}}_{\text{2}}$ in sheep in the present study, Simon *et al*. \[[@B21]\] reported that continuous iv infusion of Na~2~S for 8 hours decreased the core body temperature and ${\overset{˙}{\text{V}}\text{CO}}_{\text{2}}$ and ${\overset{˙}{\text{V}}\text{O}}_{\text{2}}$ levels in pigs, suggesting that it is possible to reduce metabolic rates in large mammals using a sulfide-based approach. However, it is important to note that hypothermia itself reduces the metabolic rate (*Q*~10~effect). Therefore, in the current study, body temperature was kept at 37°C throughout the experiment to exclude any effects of hypothermia on metabolism. Whether systemic administration of Na~2~S reduces metabolic rates in large mammals when normothermia is maintained remains to be determined.

While our findings support the inability of H~2~S to reduce metabolism in large mammals, these results differ from observations in mice in which H~2~S inhalation markedly reduced metabolism \[[@B9],[@B10],[@B22]\]. Hydrogen sulfide may be one, but not the only, trigger for murine metabolic depression. Indeed, hypoxia, anemia and exposure to carbon monoxide have been reported to reduce aerobic metabolism in mice \[[@B23]-[@B25]\], but not in large mammals \[[@B26]-[@B28]\]. Of note is that mice are known to have a much higher specific metabolic rate (approximately 168 kcal kg^-1^∙d^-1^in a 30-g mouse) than sheep (approximately 30 kcal kg^-1^∙d^-1^in a 30-kg sheep) \[[@B29]\]. In a previous study, we reported that H~2~S inhalation reduced metabolism in awake, spontaneously breathing mice by about 40% during normothermia, resulting in a specific metabolic rate of no more than approximately 100 kcal∙kg^-1^∙d^-1^\[[@B9]\]. In contrast, it has been reported that H~2~S inhalation at 100 ppm failed to reduce CO~2~production in normothermic mice that were anesthetized and mechanically ventilated \[[@B30]\]. Interestingly, in anesthetized mice studied by Baumgart *et al*. \[[@B30]\], the baseline CO~2~production rate before H~2~S inhalation was approximately 50% less than that in awake mice studied by Volpato *et al*. \[[@B9]\] in our laboratory. It is tempting to speculate that the ability of H~2~S to reduce metabolism depends on the specific metabolic rate of animals. H~2~S may reduce metabolism when the baseline rate of metabolism is high (for example, in awake mice), but not when the metabolic rate is already depressed (for example, in anesthetized mice or sheep).

Along these lines, it may be possible to reduce the metabolic rate in larger mammals using H~2~S when metabolism is increased. It has been reported that inhalation of 10 ppm H~2~S reduced oxygen consumption in exercising healthy volunteers, presumably due to inhibition of aerobiosis in exercising muscle \[[@B31]\]. Inhibitory effects of H~2~S in the presence of increased metabolism in larger mammals warrants further study.

Our results show that administration of H~2~S via a cardiopulmonary bypass circulation can cause significant dose-dependent pulmonary vasoconstriction. These observations are consistent with the pulmonary vasoconstrictor effects of H~2~S in mammalian pulmonary vessels reported by Olson *et al*. \[[@B32]\]. Although a potential role of H~2~S in hypoxia sensing (hence hypoxic pulmonary vasoconstriction) has been suggested \[[@B33]\], the mechanisms responsible for the pulmonary vasoconstrictor effects of H~2~S remain to be further elucidated.

Administration of H~2~S also tended to increase systemic vascular resistance, but resulted in systemic vasodilation after 30 minutes of ECML ventilation with 300 ppm H~2~S. This is consistent with previous reports demonstrating that H~2~S can produce both vasoconstriction and vasorelaxation in isolated rat aortic ring segments in an O~2~concentration-dependent manner. Koenitzer *et al*. \[[@B34]\] reported that H~2~S (5 to 80 μM Na~2~S solution) causes vasorelaxation at O~2~concentrations reflecting the physiological oxygen tension in the peripheral vasculature (O~2~concentration, 40 μM). In contrast, at high O~2~concentrations (O~2~, 200 μM) under which H~2~S is rapidly oxidized to sulfite, sulfate or thiosulfate, the administration of 5 to 100 μM Na~2~S causes rat aortic vasoconstriction, and more than 200 μM Na~2~S are required to cause vasorelaxation \[[@B34]\]. Along these lines, the high oxygen tension observed in sheep on ECML when ventilated with 100 and 200 ppm of H~2~S may have contributed to the systemic vasoconstrictor effects of H~2~S in the present study, whereas vasodilation was only observed at the highest H~2~S concentration (300 ppm). In addition, the O~2~dependency of H~2~S-mediated vasoconstriction may also explain why H~2~S caused vasoconstriction in the pulmonary vasculature, where O~2~availability is consistently high.

While the toxicity of inhaling high levels of H~2~S is well documented, the reported toxicity of H~2~S concentrations up to 500 ppm is almost exclusively limited to mucosal membranes and the central nervous system \[[@B35]-[@B37]\]. However, the cardiovascular toxicity of high levels of inhaled H~2~S has not been reported. The observed pulmonary hypertension and apparent changes in systemic vascular tone in the current study may therefore represent previously unrecognized toxic effects of high levels of H~2~S in the circulation.

Despite the availability of various methods used to quantify sulfide in biological fluids, it remains challenging to measure circulating plasma concentrations of H~2~S \[[@B38]\]. The methylene blue formation method employed here measures \"labile\" total sulfide liberated from sulfur compounds, but not free H~2~S in blood and tissue. In the current study, considerable sulfide concentrations were detected in plasma obtained from blood efferent from the ECML, but not in the blood samples from the femoral artery (sampled less than approximately 10 seconds after the blood left the ECML). These observations suggest a rapid uptake of H~2~S into a variety of sulfide pools once H~2~S has entered the blood stream. Of note is that the measured plasma sulfide level of 62 μM/l in the ECML efferent blood diffused with 300 ppm H~2~S was only about 3% of the expected sulfide level of approximately 2,000 μM/l assuming a blood volume of 70 ml/kg. These results are consistent with a recent report that circulating free sulfide levels are almost undetectably low at baseline and that exogenous sulfide is also rapidly removed from the circulating plasma \[[@B39]\]. Nonetheless, the pronounced vasoreactivity induced by H~2~S administration observed in the current study suggests that H~2~S (and/or its active metabolites) is transported to the periphery and exerts biological effects. The fate of exogenously administered H~2~S remains to be determined in future studies using more sensitive methods.

Although the results of the current study do not suggest that H~2~S can be used to reduce metabolic rate in larger mammals, these results do not refute the potential organ protective effects of H~2~S reported elsewhere. The dose of 134 μM/kg/h that was applied here is almost 20 times higher than the effective dose of Na~2~S reported to improve survival in mice after cardiac arrest (0.55 μg/g, that is, approximately 7 μM/kg) \[[@B12]\]. Studies by others have also shown that administration of H~2~S donors in a similarly low dose range were able to protect organs from ischemic insults in rodents and pigs without reducing metabolic rate or body temperature \[[@B14],[@B40]\]. Taken together, it is conceivable that organ-protective effects and metabolic effects of H~2~S may be mediated via two different mechanisms and/or at different concentrations.

Limitations
-----------

Measuring oxygen consumption is a valuable tool to assess metabolic rate. However, quantification of oxygen consumption in the setting of ECML requires serial simultaneous determinations of oxygen content in arterial and mixed venous blood as well as blood afferent and efferent to the ECML \[[@B41]\]. Small measuring inaccuracies in the parameters needed to calculate oxygen content (hemoglobin, oxygen saturation and tension) result in an exponential increase in the overall inaccuracy of the calculated ${\overset{˙}{\text{V}}\text{O}}_{\text{2}}$ value. In contrast, measuring CO~2~production requires only CO~2~quantification in the exhaled gas of both the natural and the artificial lung because virtually no CO~2~is present in the inhaled gas mixture, which is a major advantage to simplifying the setup and avoiding exponential error. Therefore, ${\overset{˙}{\text{V}}\text{CO}}_{\text{2}}$ may be the more reliable index for estimating the metabolic rate in this study.

The present study was designed to detect a reduction in metabolic rate of about 30% in sheep. On the basis of the variance of metabolic rates determined in pilot experiments in sheep, a sample size of 12 sheep was calculated to find a 30% reduction in metabolic rate (80% power and 5% probability of error). An interim analysis of this study (*n*= 5) did not substantiate a significant change or trend in ${\overset{˙}{\text{V}}\text{CO}}_{\text{2}}$ (Figure [3](#F3){ref-type="fig"}) and precluded additional experiments.

Conclusions
===========

The results of the present study demonstrate that ventilating an ECML with up to 300 ppm H~2~S in partial cardiopulmonary bypass circulation does not reduce CO~2~production or O~2~consumption in anesthetized sheep. Our results show that diffusion of up to 300 ppm H~2~S into blood via a membrane lung can cause dose-dependent pulmonary vasoconstriction, hypoxemia and catastrophic systemic vasodilation. These observations do not support the hypothesis that administration of a high concentration of H~2~S reduces metabolism in anesthetized large mammals. Whether the administration of H~2~S inhibits metabolism in large mammals when metabolic rate is increased (for example, systemic inflammation or exercise) remains to be determined.

Key messages
============

• High concentrations of H~2~S administered via ECML ventilation do not alter CO~2~production in sheep on partial cardiopulmonary bypass perfusion.

• In this setting, H~2~S poses the risk of pulmonary vasoconstriction, hypoxemia and systemic vasodilation.

• Therefore, administration of high concentrations of H~2~S via membrane lung may not be useful for reducing oxidative metabolism in large mammals.
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